Angelini releases positive new data on Ontozry in epilepsy

4 September 2023
angelini_2022_large

Privately-held Italian drugmaker Angelini Pharma today shared positive findings from post-hoc analyses of the C017 open-label extension (OLE) study.

The results, which are being presented as part of the 35th International Epilepsy Congress 2023 taking place in Dublin (Ireland), demonstrated that adjunctive treatment with Ontozry (cenobamate) provided long-term seizure reduction, including seizure freedom, among certain patients with uncontrolled focal-onset epilepsy.

Ontozry is an anti-seizure medication (ASM) approved in Europe in 2021 as adjunctive treatment of focal-onset seizures with or without secondary generalization in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least two anti-epileptic medicinal products. It was approved in the USA in 2019, where it is marketed under the Xcopri brand.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical